Related Experiment Video

Updated: Nov 28, 2025

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.6K

Integrin-Linked Kinase Is a Novel Therapeutic Target in Ovarian Cancer

Michael A Ulm1, Tiffany M Redfern1, Ben R Wilson1

  • 1Division of Gynecologic Oncology, West Cancer Center and Research Institute, Memphis, TN 38138, USA.

Journal of Personalized Medicine
|December 1, 2020
PubMed
Abstract

Insights

Integrin-linked kinase (ILK) is upregulated in ovarian cancer, driving tumor growth and proliferation. Inhibiting ILK shows promise as a novel therapeutic strategy for ovarian cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian cancer targeted therapeutics are limited by molecular heterogeneity.
  • Existing gene expression datasets often lack crucial pair-matched controls for identifying cancer-driving alterations.

Purpose of the Study:

  • To identify and validate novel therapeutic targets in ovarian cancer.
  • To investigate the role of Integrin-linked kinase (ILK) in ovarian cancer development and progression.

Main Methods:

  • Compared gene expression in treatment-naïve ovarian cancer tissues versus matched normal adjacent tissues using microarray.
  • Utilized Ingenuity Pathway Analysis (IPA) to identify key signaling pathways.
  • Assessed ILK expression, employed CRISPR/Cas9 for ILK knockdown, and conducted xenograft studies in mice.

Main Results:

  • Identified significant upregulation of the ILK pathway in 22/24 ovarian cancer specimens.
  • Demonstrated that ILK knockdown in SKOV3 cells reduced proliferation and tumor growth.
  • Observed inhibition of downstream AKT kinase and validated findings with an ILK-1 chemical inhibitor.

Conclusions:

  • Validated ILK as a potential therapeutic target for molecular inhibition in ovarian cancer.
  • Results suggest ILK is a key player in ovarian cancer transformation and warrants further investigation.
Keywords:
gene expressionintegrin-linked kinase (ILK)microarrayovarian cancersgRNAxenograft

More Related Videos

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells11:37

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Published on: February 18, 2015

14.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.2K
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
4.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.5K